ERBB2 and cancer: Several mechanisms of action of TZM have been proposed: (i) induction of antibody-dependent cellular cytotoxicity, (ii) prevention of e-HER2 domain cleavage and finally the most important in HER-2 overexpressed cancers, (iii) the dimerization inhibition which prevents the cell growth and proliferation [8].